Biomarker-Independent ADC Rina-S Advances to Phase 3 in Endometrial Cancer
The FRα-directed ADC rinatabart sesutecan showed disease control regardless of biomarker status
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Immunotherapy improves endometrial cancer outcomes
- Quality of Life Measures in Advanced Endometrial Cancer: A Systematic Review of Reporting Practices in Phase III Clinical Trials
- Endometrial Cancer - PMC
- Current recommendations and recent progress in endometrial cancer
- Advancements in Endometrial Cancer Research in 2024